ZE94-0605 / Eilean Therapeutics - LARVOL DELTA

A First-in-Human Study of ZE94-0605 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Eilean Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Oncology • Solid Tumor • CCNE1

Study of ZE94-0605 in Patients With Advanced Solid Tumors, With Dose Expansion Cohorts. (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: Eilean Therapeutics

New P1 trial • Oncology • Solid Tumor • CCNE1

Synergy evaluation of quisinostat (HDAC I Inhibitor) and ZE94-0605 (CDK2 Inhibitor) in various in vitro and in vivo models (AACR 2026) - "Combining quisinostat with the CDK2 inhibitor ZE94-0605 yields synergistic efficacy and superior outcomes in the OVCAR-3 xenograft model. Our findings indicate that quisinostat enhances in vivo therapeutic efficacy and supports further evaluation of this combination strategy for ovarian and other cancers."

Preclinical • Brain Cancer • Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor

Eilean Therapeutics…announced the presentation of preclinical data for its novel, brain-permeable CDK2 inhibitor at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (PRNewswire) - "The compound demonstrates high selectivity for CDK2 over other cyclin-dependent kinases (CDKs), excellent safety and tolerability, and a broad therapeutic window in models of multiple cyclin-E1 (CCNE1)–CDK2–dependent neoplasms....Eilean plans to...advance this highly selective CDK2 inhibitor into a First-in-Human clinical study in Q4 2025."

New trial • Preclinical • Oncology